A recent study found that upregulation of PD-L1 in nasopharyngeal carcinoma cells is associated with active glycolysis, and sirilimarine (A drug used in hepatitis, cirrhosis, and liver protection) interferes with HIF-1α/LDH-A mediated glucose metabolism and shifts to mitochondrial oxidative phosphorylation, reducing PD-L1 expression (140). Here, CD274 is linked to nasopharyngeal carcinoma.